Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2006.07.9525 on April 23 2007

Journal of Clinical Oncology, Vol 25, No 15 (May 20), 2007: pp. 1960-1966
© 2007 American Society of Clinical Oncology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moore, M. J.
Right arrow Articles by Parulekar, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moore, M. J.
Right arrow Articles by Parulekar, W.
Related Articles
Right arrowRelated Editorial
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Malcolm J. Moore, David Goldstein, John Hamm, Arie Figer, Joel R. Hecht, Steven Gallinger, Heather J. Au, Pawel Murawa, David Walde, Robert A. Wolff, Daniel Campos, Robert Lim, Keyue Ding, Gary Clark, Theodora Voskoglou-Nomikos, Mieke Ptasynski, Wendy Parulekar

From the Divisions of Medical Oncology, Hematology, and Surgical Oncology, Princess Margaret Hospital, Toronto; National Cancer Institute of Canada Clinical Trials Group, Kingston; Algoma District Cancer Program, Sault Ste Marie, Ontario; Cross Cancer Institute, Edmonton, Alberta, Canada; the Australasian Gastrointestinal Tumor Group, Sydney, Australia; Norton Healthcare Pavilion, Louisville, KY; UCLA Medical Center, Los Angeles, CA; M. D. Anderson Cancer Centre, Houston, TX; OSI Pharmaceuticals, Boulder, CO; Sourasky Medical Centre, Tel Aviv, Israel; Great Poland Centre for Oncology, Poznan, Poland; Confidence Medical Centre, San Isidro, Argentina; and the National University Hospital, Singapore, Singapore

Address reprint requests to Malcolm J. Moore, MD, Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Ave, Toronto, Canada M5G 2M9; e-mail: malcolm.moore{at}uhn.on.ca

Purpose Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic tumors often overexpress human epidermal growth factor receptor type 1 (HER1/EGFR) and this is associated with a worse prognosis. We studied the effects of adding the HER1/EGFR-targeted agent erlotinib to gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.

Patients and Methods Patients were randomly assigned 1:1 to receive standard gemcitabine plus erlotinib (100 or 150 mg/d orally) or gemcitabine plus placebo in a double-blind, international phase III trial. The primary end point was overall survival.

Results A total of 569 patients were randomly assigned. Overall survival based on an intent-to-treat analysis was significantly prolonged on the erlotinib/gemcitabine arm with a hazard ratio (HR) of 0.82 (95% CI, 0.69 to 0.99; P = .038, adjusted for stratification factors; median 6.24 months v 5.91 months). One-year survival was also greater with erlotinib plus gemcitabine (23% v 17%; P = .023). Progression-free survival was significantly longer with erlotinib plus gemcitabine with an estimated HR of 0.77 (95% CI, 0.64 to 0.92; P = .004). Objective response rates were not significantly different between the arms, although more patients on erlotinib had disease stabilization. There was a higher incidence of some adverse events with erlotinib plus gemcitabine, but most were grade 1 or 2.

Conclusion To our knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine. The recommended dose of erlotinib with gemcitabine for this indication is 100 mg/d.

published online ahead of print at www.jco.org on April 23, 2007.

Supported in part by OSI Pharmaceuticals, Melville, NY.

Presented in part at the American Society of Clinical Oncology Gastrointestinal Symposium, Hollywood, FL, January 27-29 2005; and the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005.

A list of participating investigators can be found in the online-only Acknowledgment.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Editorial

  • Lessons Learned in the Management of Advanced Pancreatic Cancer
    Eric Van Cutsem, Chris Verslype, and Patrick A. Grusenmeyer
    JCO 2007 25: 1949-1952 [Full Text]

Related Correspondence

  • Erlotinib in Pancreatic Cancer Patients: Do We Need More Information From the NCIC CTG Trial?
    Mario Mandalà, Cecilia Moro, Roberto Labianca, and Gianluigi Ferretti
    JCO 2007 25: 4320-4321 [Full Text]
  • Does a Statistically Significant Survival Benefit of Erlotinib Plus Gemcitabine for Advanced Pancreatic Cancer Translate Into Clinical Significance and Value?
    Rebecca A. Miksad, Lowell Schnipper, and Michael Goldstein
    JCO 2007 25: 4506-4507 [Full Text]
  • Erlotinib in Pancreatic Cancer: Are Tumor Cells the (only) Target?
    Nicola Normanno and Antonella De Luca
    JCO 2007 25: 5836-5837 [Full Text]


This article has been cited by other articles:


Home page
 JCOHome page
N. Starling, D. Watkins, D. Cunningham, J. Thomas, J. Webb, G. Brown, K. Thomas, J. Oates, and I. Chau
Dose Finding and Early Efficacy Study of Gemcitabine Plus Capecitabine in Combination With Bevacizumab Plus Erlotinib in Advanced Pancreatic Cancer
J. Clin. Oncol., November 20, 2009; 27(33): 5499 - 5505.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Philip, M. Mooney, D. Jaffe, G. Eckhardt, M. Moore, N. Meropol, L. Emens, E. O'Reilly, M. Korc, L. Ellis, et al.
Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment
J. Clin. Oncol., November 20, 2009; 27(33): 5660 - 5669.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. H. Kulke, M. A. Tempero, D. Niedzwiecki, D. R. Hollis, H. L. Kindler, M. Cusnir, P. C. Enzinger, S. M. Gorsch, R. M. Goldberg, and R. J. Mayer
Randomized Phase II Study of Gemcitabine Administered at a Fixed Dose Rate or in Combination With Cisplatin, Docetaxel, or Irinotecan in Patients With Metastatic Pancreatic Cancer: CALGB 89904
J. Clin. Oncol., November 20, 2009; 27(33): 5506 - 5512.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Tabernero and T. Macarulla
Changing the Paradigm in Conducting Randomized Clinical Studies in Advanced Pancreatic Cancer: An Opportunity for Better Clinical Development
J. Clin. Oncol., November 20, 2009; 27(33): 5487 - 5491.
[Full Text] [PDF]

Home page
 JCOHome page
D. Cunningham, I. Chau, D. D. Stocken, J. W. Valle, D. Smith, W. Steward, P. G. Harper, J. Dunn, C. Tudur-Smith, J. West, et al.
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
J. Clin. Oncol., November 20, 2009; 27(33): 5513 - 5518.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. D. Saad, A. Katz, P. M. Hoff, and M. Buyse
Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
Ann. Onc., November 9, 2009; (2009) mdp523v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Larbouret, B. Robert, C. Bascoul-Mollevi, F. Penault-Llorca, A. Ho-Pun-Cheung, S. Morisseau, I. Navarro-Teulon, J.-P. Mach, A. Pelegrin, and D. Azria
Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts
Ann. Onc., November 4, 2009; (2009) mdp496v1.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Zhang, T. A. LaFortune, S. Krishnamurthy, F. J. Esteva, M. Cristofanilli, P. Liu, A. Lucci, B. Singh, M.-C. Hung, G. N. Hortobagyi, et al.
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer
Clin. Cancer Res., November 1, 2009; 15(21): 6639 - 6648.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Melisi, V. Ossovskaya, C. Zhu, R. Rosa, J. Ling, P. M. Dougherty, B. M. Sherman, J. L. Abbruzzese, and P. J. Chiao
Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity
Clin. Cancer Res., October 15, 2009; 15(20): 6367 - 6377.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer
J Natl Cancer Inst, October 7, 2009; 101(19): 1308 - 1324.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
A. Soeda, Y. Morita-Hoshi, H. Makiyama, C. Morizane, H. Ueno, M. Ikeda, T. Okusaka, S. Yamagata, N. Takahashi, I. Hyodo, et al.
Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer
Jpn. J. Clin. Oncol., October 1, 2009; (2009) hyp112v1.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Bekaii-Saab, J. Markowitz, N. Prescott, W. Sadee, N. Heerema, L. Wei, Z. Dai, A. Papp, A. Campbell, K. Culler, et al.
A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas
Clin. Cancer Res., September 15, 2009; 15(18): 5895 - 5901.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
N. Ozaki, M. Ohmuraya, M. Hirota, S. Ida, J. Wang, H. Takamori, S. Higashiyama, H. Baba, and K.-i. Yamamura
Serine Protease Inhibitor Kazal Type 1 Promotes Proliferation of Pancreatic Cancer Cells through the Epidermal Growth Factor Receptor
Mol. Cancer Res., September 1, 2009; 7(9): 1572 - 1581.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Poplin, Y. Feng, J. Berlin, M. L. Rothenberg, H. Hochster, E. Mitchell, S. Alberts, P. O'Dwyer, D. Haller, P. Catalano, et al.
Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
J. Clin. Oncol., August 10, 2009; 27(23): 3778 - 3785.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
T. Fojo and C. Grady
How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
J Natl Cancer Inst, August 5, 2009; 101(15): 1044 - 1048.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Laurent, E. Monsaert, T. Boterberg, A. Demols, I. Borbath, M. Polus, A. Hendlisz, B. de Hemptinne, C. Mahin, P. Scalliet, et al.
Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study
Ann. Onc., August 1, 2009; 20(8): 1369 - 1374.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
A. BAKSHANDEH-BATH, A. S. STOLTZ, N. HOMANN, T. WAGNER, S. STOLTING, and S. O. PETERS
Preclinical and Clinical Aspects of Carboplatin and Gemcitabine Combined with Whole-body Hyperthermia for Pancreatic Adenocarcinoma
Anticancer Res, August 1, 2009; 29(8): 3069 - 3077.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
T. UWAGAWA, P. J. CHIAO, T. GOCHO, S. HIROHARA, T. MISAWA, and K. YANAGA
Combination Chemotherapy of Nafamostat Mesilate with Gemcitabine for Pancreatic Cancer Targeting NF-{kappa}B Activation
Anticancer Res, August 1, 2009; 29(8): 3173 - 3178.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. H. Thoennissen, G. B. Iwanski, N. B. Doan, R. Okamoto, P. Lin, S. Abbassi, J. H. Song, D. Yin, M. Toh, W. D. Xie, et al.
Cucurbitacin B Induces Apoptosis by Inhibition of the JAK/STAT Pathway and Potentiates Antiproliferative Effects of Gemcitabine on Pancreatic Cancer Cells
Cancer Res., July 15, 2009; 69(14): 5876 - 5884.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Banerjee, Z. Wang, D. Kong, and F. H. Sarkar
3,3'-Diindolylmethane Enhances Chemosensitivity of Multiple Chemotherapeutic Agents in Pancreatic Cancer
Cancer Res., July 1, 2009; 69(13): 5592 - 5600.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
E. T.H. Yeh and C. L. Bickford
Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.
J. Am. Coll. Cardiol., June 16, 2009; 53(24): 2231 - 2247.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Van Cutsem, W. L. Vervenne, J. Bennouna, Y. Humblet, S. Gill, J.-L. Van Laethem, C. Verslype, W. Scheithauer, A. Shang, J. Cosaert, et al.
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
J. Clin. Oncol., May 1, 2009; 27(13): 2231 - 2237.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Cascinu, S. Jelic, and On behalf of the ESMO Guidelines Working Group
Pancreatic cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc., May 1, 2009; 20(suppl_4): iv37 - iv40.
[Full Text] [PDF]

Home page
 JCOHome page
C. A. Iacobuzio-Donahue, B. Fu, S. Yachida, M. Luo, H. Abe, C. M. Henderson, F. Vilardell, Z. Wang, J. W. Keller, P. Banerjee, et al.
DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
J. Clin. Oncol., April 10, 2009; 27(11): 1806 - 1813.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
V Martin, L Mazzucchelli, and M Frattini
An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology
J. Clin. Pathol., April 1, 2009; 62(4): 314 - 324.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
W. W. Ma and A. A. Adjei
Novel Agents on the Horizon for Cancer Therapy
CA Cancer J Clin, March 1, 2009; 59(2): 111 - 137.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
S. MIYAMOTO, T. FUKAMI, H. YAGI, M. KUROKI, and F. YOTSUMOTO
Potential for Molecularly Targeted Therapy against Epidermal Growth Factor Receptor Ligands
Anticancer Res, March 1, 2009; 29(3): 823 - 830.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. Pellegrinotti, F. L. Fimognari, A. Franco, L. Repetto, and R. Pastorelli
Erlotinib-Induced Hepatitis Complicated by Fatal Lactic Acidosis in an Elderly Man With Lung Cancer
Ann. Pharmacother., March 1, 2009; 43(3): 542 - 545.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Freidlin and E. L. Korn
Monitoring for Lack of Benefit: A Critical Component of a Randomized Clinical Trial
J. Clin. Oncol., February 1, 2009; 27(4): 629 - 633.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. J. Guarino, C. J. Schneider, M. A. Hosford, J. R. Brahmer, C. M. Rudin, F. G. Finckenstein, R. E. Philip-Norton, H. Lu, M. R. Weber, and D. S. Ettinger
Dual Inhibition of the Epidermal Growth Factor Receptor Pathway with Cetuximab and Erlotinib: A Phase I Study in Patients with Advanced Solid Malignancies
Oncologist, February 1, 2009; 14(2): 119 - 124.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. J. Stewart and R. Kurzrock
Cancer: The Road to Amiens
J. Clin. Oncol., January 20, 2009; 27(3): 328 - 333.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
E. S. Seeley, C. Carriere, T. Goetze, D. S. Longnecker, and M. Korc
Pancreatic Cancer and Precursor Pancreatic Intraepithelial Neoplasia Lesions Are Devoid of Primary Cilia
Cancer Res., January 15, 2009; 69(2): 422 - 430.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. M. Wolpin, A. F. Hezel, T. Abrams, L. S. Blaszkowsky, J. A. Meyerhardt, J. A. Chan, P. C. Enzinger, B. Allen, J. W. Clark, D. P. Ryan, et al.
Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
J. Clin. Oncol., January 10, 2009; 27(2): 193 - 198.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
M. K. Kim, K. H. Lee, B. I. Jang, T. N. Kim, J. R. Eun, S. H. Bae, H. M. Ryoo, S. A. Lee, and M. S. Hyun
S-1 and Gemcitabine as an Outpatient-based Regimen in Patients with Advanced or Metastatic Pancreatic Cancer
Jpn. J. Clin. Oncol., January 1, 2009; 39(1): 49 - 53.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. A. Yu, C. Galanis, Y. Woo, N. Chen, Q. Zhang, Y. Fong, and A. A. Szalay
Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68
Mol. Cancer Ther., January 1, 2009; 8(1): 141 - 151.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. A. Dallas, M. J. Gray, L. Xia, F. Fan, G. van Buren II, P. Gaur, S. Samuel, S. J. Lim, T. Arumugam, V. Ramachandran, et al.
Neuropilin-2-Mediated Tumor Growth and Angiogenesis in Pancreatic Adenocarcinoma
Clin. Cancer Res., December 15, 2008; 14(24): 8052 - 8060.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Pan, T. Arumugam, T. Yamamoto, P. A. Levin, V. Ramachandran, B. Ji, G. Lopez-Berestein, P. E. Vivas-Mejia, A. K. Sood, D. J. McConkey, et al.
Nuclear Factor-{kappa}B p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells
Clin. Cancer Res., December 15, 2008; 14(24): 8143 - 8151.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Marten, N. Zeiss, S. Serba, S. Mehrle, M. von Lilienfeld-Toal, and J. Schmidt
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma
Mol. Cancer Ther., November 1, 2008; 7(11): 3624 - 3631.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. Morgan, L. A. Parsels, J. Maybaum, and T. S. Lawrence
Improving Gemcitabine-Mediated Radiosensitization Using Molecularly Targeted Therapy: A Review
Clin. Cancer Res., November 1, 2008; 14(21): 6744 - 6750.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. I. Jakacki, M. Hamilton, R. J. Gilbertson, S. M. Blaney, J. Tersak, M. D. Krailo, A. M. Ingle, S. D. Voss, J. E. Dancey, and P. C. Adamson
Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study
J. Clin. Oncol., October 20, 2008; 26(30): 4921 - 4927.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
H. Le, A. Ziogas, J. M. Rhee, J. G. Lee, S. M. Lipkin, and J. A. Zell
A Population-Based, Descriptive Analysis of Malignant Intraductal Papillary Mucinous Neoplasms of the Pancreas
Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2737 - 2741.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Vonlaufen, P. A. Phillips, Z. Xu, D. Goldstein, R. C. Pirola, J. S. Wilson, and M. V. Apte
Pancreatic Stellate Cells and Pancreatic Cancer Cells: An Unholy Alliance
Cancer Res., October 1, 2008; 68(19): 7707 - 7710.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. R. Tan, W. S. Brenner, J. Picus, S. Marsh, F. Gao, C. Fournier, P. M. Fracasso, J. James, J. L. Yen-Revollo, and H. L. Mcleod
Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies
Ann. Onc., October 1, 2008; 19(10): 1742 - 1748.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. L. Arteaga, A. O'Neill, S. L. Moulder, M. Pins, J. A. Sparano, G. W. Sledge, and N. E. Davidson
A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer
Clin. Cancer Res., October 1, 2008; 14(19): 6277 - 6283.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
S. A. Danovi, H. H. Wong, and N. R. Lemoine
Targeted therapies for pancreatic cancer
Br. Med. Bull., September 1, 2008; 87(1): 97 - 130.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Gravis, F. Bladou, N. Salem, A. Goncalves, B. Esterni, J. Walz, S. Bagattini, M. Marcy, S. Brunelle, and P. Viens
Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer
Ann. Onc., September 1, 2008; 19(9): 1624 - 1628.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
P Ghaneh, E Costello, and J P Neoptolemos
Biology and management of pancreatic cancer
Postgrad. Med. J., September 1, 2008; 84(995): 478 - 497.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. Morgan, L. A. Parsels, L. E. Kollar, D. P. Normolle, J. Maybaum, and T. S. Lawrence
The Combination of Epidermal Growth Factor Receptor Inhibitors with Gemcitabine and Radiation in Pancreatic Cancer
Clin. Cancer Res., August 15, 2008; 14(16): 5142 - 5149.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Bernhard, D. Dietrich, W. Scheithauer, D. Gerber, G. Bodoky, T. Ruhstaller, B. Glimelius, E. Bajetta, J. Schuller, P. Saletti, et al.
Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial--SAKK 44/00-CECOG/PAN.1.3.001
J. Clin. Oncol., August 1, 2008; 26(22): 3695 - 3701.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. S. Pino, M. Balsamo, F. Di Modugno, M. Mottolese, M. Alessio, E. Melucci, M. Milella, D. J. McConkey, U. Philippar, F. B. Gertler, et al.
Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines
Clin. Cancer Res., August 1, 2008; 14(15): 4943 - 4950.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Merchant and J. Berlin
Past and Future of Pancreas Cancer: Are We Ready to Move Forward Together?
J. Clin. Oncol., July 20, 2008; 26(21): 3478 - 3480.
[Full Text] [PDF]

Home page
 Ann OncolHome page
Y. J. Chua and J. R. Zalcberg
Pancreatic cancer--is the wall crumbling?
Ann. Onc., July 1, 2008; 19(7): 1224 - 1230.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Quinkler, S. Hahner, S. Wortmann, S. Johanssen, P. Adam, C. Ritte, C. Strasburger, B. Allolio, and M. Fassnacht
Treatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine
J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2057 - 2062.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Ali, S. Banerjee, A. Ahmad, B. F. El-Rayes, P. A. Philip, and F. H. Sarkar
Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer
Mol. Cancer Ther., June 1, 2008; 7(6): 1708 - 1719.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. N. Contessa, M. S. Bhojani, H. H. Freeze, A. Rehemtulla, and T. S. Lawrence
Inhibition of N-Linked Glycosylation Disrupts Receptor Tyrosine Kinase Signaling in Tumor Cells
Cancer Res., May 15, 2008; 68(10): 3803 - 3809.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Nieto, M. L. Grossbard, and P. Kozuch
Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty?
Oncologist, May 1, 2008; 13(5): 562 - 576.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Jimeno, A. C. Tan, J. Coffa, N.V. Rajeshkumar, P. Kulesza, B. Rubio-Viqueira, J. Wheelhouse, B. Diosdado, W. A. Messersmith, C. Iacobuzio-Donahue, et al.
Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer
Cancer Res., April 15, 2008; 68(8): 2841 - 2849.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Baselga and N. Rosen
Determinants of RASistance to Anti-Epidermal Growth Factor Receptor Agents
J. Clin. Oncol., April 1, 2008; 26(10): 1582 - 1584.
[Full Text] [PDF]

Home page
 JCOHome page
R. G. Amado, M. Wolf, M. Peeters, E. Van Cutsem, S. Siena, D. J. Freeman, T. Juan, R. Sikorski, S. Suggs, R. Radinsky, et al.
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
J. Clin. Oncol., April 1, 2008; 26(10): 1626 - 1634.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F. Cappuzzo, G. Finocchiaro, E. Rossi, P.A. Janne, C. Carnaghi, C. Calandri, K. Bencardino, C. Ligorio, F. Ciardiello, T. Pressiani, et al.
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
Ann. Onc., April 1, 2008; 19(4): 717 - 723.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
F. Ciardiello and G. Tortora
EGFR Antagonists in Cancer Treatment
N. Engl. J. Med., March 13, 2008; 358(11): 1160 - 1174.
[Full Text] [PDF]

Home page
 JCOHome page
C. K. Daugherty, M. J. Ratain, E. J. Emanuel, A. T. Farrell, and R. L. Schilsky
Ethical, Scientific, and Regulatory Perspectives Regarding the Use of Placebos in Cancer Clinical Trials
J. Clin. Oncol., March 10, 2008; 26(8): 1371 - 1378.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Boeck and V. Heinemann
Second-Line Therapy in Gemcitabine-Pretreated Patients With Advanced Pancreatic Cancer
J. Clin. Oncol., March 1, 2008; 26(7): 1178 - 1179.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Laheru, E. Lutz, J. Burke, B. Biedrzycki, S. Solt, B. Onners, I. Tartakovsky, J. Nemunaitis, D. Le, E. Sugar, et al.
Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
Clin. Cancer Res., March 1, 2008; 14(5): 1455 - 1463.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H. Burris III and C. Rocha-Lima
New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways
Oncologist, March 1, 2008; 13(3): 289 - 298.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
A. A. Garcia
Small Molecules: Big Changes in the Cancer Treatment Paradigm
Journal of Pharmacy Practice, February 1, 2008; 21(1): 17 - 35.
[Abstract] [PDF]

Home page
 Ann OncolHome page
S. Boeck, T. Hoehler, G. Seipelt, R. Mahlberg, A. Wein, A. Hochhaus, H.-P. Boeck, B. Schmid, E. Kettner, M. Stauch, et al.
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer
Ann. Onc., February 1, 2008; 19(2): 340 - 347.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Van Cutsem, C. Verslype, P. Beale, S. Clarke, R. Bugat, A. Rakhit, S. H. Fettner, U. Brennscheidt, A. Feyereislova, and J.-P Delord
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients
Ann. Onc., February 1, 2008; 19(2): 332 - 339.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Grothey, E. E. Hedrick, R. D. Mass, S. Sarkar, S. Suzuki, R. K. Ramanathan, H. I. Hurwitz, R. M. Goldberg, and D. J. Sargent
Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107
J. Clin. Oncol., January 10, 2008; 26(2): 183 - 189.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol PractHome page
M. A. Tempero
How I Treat Pancreatic Ductal Adenocarcinoma
J. Oncol. Pract, January 1, 2008; 4(1): 46 - 47.
[Full Text] [PDF]

Home page
 Toxicol PatholHome page
D. W. Hedley, S. Chow, C. Goolsby, and T. V. Shankey
Pharmacodynamic Monitoring of Molecular-Targeted Agents in the Peripheral Blood of Leukemia Patients Using Flow Cytometry
Toxicol Pathol, January 1, 2008; 36(1): 133 - 139.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
G. Butturini, D. D. Stocken, M. N. Wente, H. Jeekel, J. H. G. Klinkenbijl, K. E. Bakkevold, T. Takada, H. Amano, C. Dervenis, C. Bassi, et al.
Influence of Resection Margins and Treatment on Survival in Patients With Pancreatic Cancer: Meta-analysis of Randomized Controlled Trials
Arch Surg, January 1, 2008; 143(1): 75 - 83.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Folprecht, J. Tabernero, C.-H. Kohne, C. Zacharchuk, L. Paz-Ares, F. Rojo, S. Quinn, E. Casado, R. Salazar, R. Abbas, et al.
Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer
Clin. Cancer Res., January 1, 2008; 14(1): 215 - 223.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Normanno and A. De Luca
Erlotinib in Pancreatic Cancer: Are Tumor Cells the (only) Target?
J. Clin. Oncol., December 20, 2007; 25(36): 5836 - 5837.
[Full Text] [PDF]

Home page
 JCOHome page
J. A. Ajani
The Area Between the Curves Gets No Respect: Is It Because of the Median Madness?
J. Clin. Oncol., December 1, 2007; 25(34): 5531 - 5531.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Shi, X.-X. Peng, I.-W. Kim, S. Shukla, Q.-S. Si, R. W. Robey, S. E. Bates, T. Shen, C. R. Ashby Jr., L.-W. Fu, et al.
Erlotinib (Tarceva, OSI-774) Antagonizes ATP-Binding Cassette Subfamily B Member 1 and ATP-Binding Cassette Subfamily G Member 2 Mediated Drug Resistance
Cancer Res., November 15, 2007; 67(22): 11012 - 11020.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Rajasekhar and T. J. George Jr.
Gemcitabine-Induced Reversible Posterior Leukoencephalopathy Syndrome: A Case Report and Review of the Literature
Oncologist, November 1, 2007; 12(11): 1332 - 1335.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. H. Kulke, L. S. Blaszkowsky, D. P. Ryan, J. W. Clark, J. A. Meyerhardt, A. X. Zhu, P. C. Enzinger, E. L. Kwak, A. Muzikansky, C. Lawrence, et al.
Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer
J. Clin. Oncol., October 20, 2007; 25(30): 4787 - 4792.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. P. Desai, E. Ben-Josef, D. P. Normolle, I. R. Francis, J. K. Greenson, D. M. Simeone, A. E. Chang, L. M. Colletti, T. S. Lawrence, and M. M. Zalupski
Phase I Study of Oxaliplatin, Full-Dose Gemcitabine, and Concurrent Radiation Therapy in Pancreatic Cancer
J. Clin. Oncol., October 10, 2007; 25(29): 4587 - 4592.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Ferrari and P. Foa
Targeted Therapies: Cui Prodest?
J. Clin. Oncol., October 10, 2007; 25(29): 4691 - 4692.
[Full Text] [PDF]

Home page
 JCOHome page
R. A. Miksad, L. Schnipper, and M. Goldstein
Does a Statistically Significant Survival Benefit of Erlotinib Plus Gemcitabine for Advanced Pancreatic Cancer Translate Into Clinical Significance and Value?
J. Clin. Oncol., October 1, 2007; 25(28): 4506 - 4507.
[Full Text] [PDF]

Home page
 JCOHome page
M. J. Moore, H. J. Au, and W. Parulekar
In Reply
J. Clin. Oncol., October 1, 2007; 25(28): 4508 - 4508.
[Full Text] [PDF]

Home page
 JCOHome page
M. Mandala, C. Moro, R. Labianca, and G. Ferretti
Erlotinib in Pancreatic Cancer Patients: Do We Need More Information From the NCIC CTG Trial?
J. Clin. Oncol., September 20, 2007; 25(27): 4320 - 4321.
[Full Text] [PDF]

Home page
 Ann OncolHome page
S Boeck, A Wollenberg, and V Heinemann
Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib
Ann. Onc., September 1, 2007; 18(9): 1582 - 1583.
[Full Text] [PDF]

Home page
 GutHome page
P. Ghaneh, E. Costello, and J. P Neoptolemos
Biology and management of pancreatic cancer
Gut, August 1, 2007; 56(8): 1134 - 1152.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Perez-Soler
Erlotinib: Recent Clinical Results and Ongoing Studies in Non Small Cell Lung Cancer
Clin. Cancer Res., August 1, 2007; 13(15): 4589s - 4592s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Wacker, T. Nagrani, J. Weinberg, K. Witt, G. Clark, and P. J. Cagnoni
Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies
Clin. Cancer Res., July 1, 2007; 13(13): 3913 - 3921.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Van Cutsem, C. Verslype, and P. A. Grusenmeyer
Lessons Learned in the Management of Advanced Pancreatic Cancer
J. Clin. Oncol., May 20, 2007; 25(15): 1949 - 1952.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online